ASH 2022 | Phase I study of neihulizumab in patients with SR-aGvHD or TR-aGvHD
Sameem Abedin, MD, Medical College of Wisconsin, Milwaukee, WI, summarizes the results of a Phase I study that assessed the pharmacokinetics and efficacy of neihulizumab in patients with steroid-refractory (SR) and treatment-refractory (TR) acute graft-versus-host disease (aGvHD). This study demonstrated that patients saw improved outcomes when treated with neihulizumab, with improvements in skin manifestations and durable survival. Hence, this trial’s results demonstrated that neihulizumab treatment is likely to benefit R/R patients with aGVHD in combination with ruxolitinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Helsinn Healthcare: Research Funding; Pfizer: Research Funding; Actinium Pharmaceuticals: Research Funding; AltruBio Inc.: Research Funding; Stemline: Honoraria; Amgen: Honoraria; Incyte: Research Funding; AbbVie: Honoraria; Daichi Sankyo: Honoraria; Servier: Honoraria.
